Acadia Pharmaceuticals (ACAD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.02+0.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACAD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 1,138.6 | 1,071.5 | 957.8 | 726.4 | 517.2 | 484.1 | 441.8 | 339.1 | 223.8 | 124.9 | 17.3 | 0.1 | 0.1 | 1.1 | 4.9 | 2.1 |
| Total Revenues | — | — | — | 726.4 | 517.2 | 484.1 | 441.8 | 339.1 | 223.8 | 124.9 | 17.3 | 0.1 | 0.1 | 1.1 | 4.9 | 2.1 |
| Cost of Revenues | 101.0 | 89.0 | 81.8 | 41.6 | 10.2 | 19.1 | 10.2 | 11.3 | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | 684.8 | 507.1 | 473.3 | 431.5 | 327.7 | 211.4 | 115.8 | 14.3 | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 620.3 | 548.9 | 488.4 | 406.6 | 369.1 | 396.0 | 388.7 | 325.6 | 265.8 | 255.1 | 186.5 | — | — | — | — | — |
| R&D Expenses | 331.0 | 328.8 | 303.2 | 351.6 | 361.6 | 239.4 | 319.1 | 240.4 | 187.2 | 149.2 | 99.3 | 73.9 | 60.6 | 26.7 | 18.8 | 17.3 |
| Operating Income | 86.4 | 104.8 | 230.8 | (73.4) | (223.6) | (170.4) | (286.6) | (246.5) | (247.4) | (292.4) | (272.8) | (164.6) | (93.2) | (38.3) | (20.9) | (22.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| EBT, Incl. Unusual Items | 121.4 | 138.9 | 258.1 | (51.0) | (213.4) | (167.5) | (281.0) | (234.4) | (243.9) | (288.3) | (270.1) | (164.1) | — | — | — | — |
| Income Tax Expense | (259.1) | (252.1) | 31.6 | 10.3 | 2.5 | 0.4 | 0.6 | 0.9 | 1.3 | 1.1 | 1.3 | 0.3 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||||
| Net Income | 380.5 | 391.0 | 226.5 | (61.0) | (214.0) | (168.0) | (281.6) | (235.3) | (245.2) | (289.4) | (271.4) | (164.4) | (92.5) | (37.9) | (20.8) | (22.8) |
| Per Share | ||||||||||||||||
| Basic EPS | 2.22 | 2.32 | 1.37 | (0.37) | (1.34) | (1.05) | (1.79) | — | — | — | — | — | — | — | (0.38) | (0.44) |
| Diluted EPS | 2.20 | 2.30 | 1.36 | (0.37) | (1.34) | (1.05) | (1.79) | — | — | — | — | — | — | — | (0.38) | (0.44) |
| Revenue per Share | 6.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 171.6 | 168.4 | 165.7 | 163.8 | 161.7 | 0.2 | 0.2 | — | — | — | — | — | — | — | 55.1 | 52.2 |
| Diluted Weighted Avg Shares | 172.9 | 169.9 | 166.4 | 163.8 | 161.7 | 0.2 | 0.2 | — | — | — | — | — | — | — | 55.1 | 52.2 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | (93.0) | (38.2) | — | — |
| EBIT | 86.4 | 104.8 | 230.8 | (73.4) | (223.6) | (170.4) | (286.6) | (246.5) | (247.4) | (292.4) | (272.8) | (164.6) | (93.2) | (38.3) | (20.9) | (22.9) |
| Effective Tax Rate | -213.5% | — | — | -20.1% | -1.2% | -0.2% | -0.2% | -0.4% | -0.5% | -0.4% | -0.5% | -0.2% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.